biOasis Technologies Inc.

Ordinary Shares International Reporting
Contact Info
  • Suite 130-10691 Shellbridge Way
  • Richmond, BC V6X 2W8
  • Canada

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report May 31, 2017 Interim Financial Report
Fiscal Year End 2/28
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 5122 - Drugs, proprietaries, and sundries
Incorporated In: British Columbia, Canada
Year of Inc. 2006
Employees 8 a/o Feb 05, 2014
Company Officers/Contacts
Rob Hutchison CEO
Judi Dalling CFO, Corporate Secretary
Company Directors
Rob Hutchison Chairman, Executive Chairman
Ron Erickson
Chris Fibiger
Greg Gubitz
Michael Hutchison
Terry Pearson
Service Providers
Accounting/Auditing Firm
Manning Elliott LLP
1050 W. Pender Street
11th Floor
Vancouver, BC, V6E 3S7
Securities Counsel
Tanya Markovich Law Corporation
Suite 1780 - 400 Burrard Street
Vancouver, BC, V6C 3A6
Investor Relations Firm

Not Available
BIOAF Security Details
Share Structure
Market Value1 $31,752,536 a/o Oct 20, 2017
Authorized Shares Unlimited a/o Oct 04, 2016
Outstanding Shares 45,654,257 a/o Jan 30, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 39,011,827 a/o Oct 04, 2016
Par Value No Par Value
Transfer Agent(s)
Shareholders of Record Not Available
Non US Stock Exchange Listing
BTI - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 26,664 (19.94%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security